Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?

Acute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functiona...

Full description

Bibliographic Details
Main Authors: Tine Tricot, Jolan De Boeck, Catherine Verfaillie
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/9/3/566
id doaj-3a9b611eb3ec4afb8d4d9beec9cf19f3
record_format Article
spelling doaj-3a9b611eb3ec4afb8d4d9beec9cf19f32020-11-25T01:19:53ZengMDPI AGCells2073-44092020-02-019356610.3390/cells9030566cells9030566Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?Tine Tricot0Jolan De Boeck1Catherine Verfaillie2Stem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumStem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumStem Cell Institute Leuven, KU Leuven, 3000 Leuven, BelgiumAcute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functional hepatocytes, can be an acceptable alternative. The gold standard for this therapy is the use of primary human hepatocytes, isolated from livers that are not suitable for whole organ transplantations. Unfortunately, primary human hepatocytes are scarcely available, which has led to the evaluation of alternative sources of functional hepatocytes. In this review, we will compare the ability of most of these candidate alternative cell sources to engraft and repopulate the liver of preclinical animal models with the repopulation ability found with primary human hepatocytes. We will discuss the current shortcomings of the different cell types, and some of the next steps that we believe need to be taken to create alternative hepatocyte progeny capable of regenerating the failing liver.https://www.mdpi.com/2073-4409/9/3/566hepatocyte transplantationpreclinical mouse models for liver damageprimary human hepatocyteshepatocyte expansionipscsmscs
collection DOAJ
language English
format Article
sources DOAJ
author Tine Tricot
Jolan De Boeck
Catherine Verfaillie
spellingShingle Tine Tricot
Jolan De Boeck
Catherine Verfaillie
Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
Cells
hepatocyte transplantation
preclinical mouse models for liver damage
primary human hepatocytes
hepatocyte expansion
ipscs
mscs
author_facet Tine Tricot
Jolan De Boeck
Catherine Verfaillie
author_sort Tine Tricot
title Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
title_short Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
title_full Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
title_fullStr Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
title_full_unstemmed Alternative Cell Sources for Liver Parenchyma Repopulation: Where Do We Stand?
title_sort alternative cell sources for liver parenchyma repopulation: where do we stand?
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2020-02-01
description Acute and chronic liver failure is a highly prevalent medical condition with high morbidity and mortality. Currently, the therapy is orthotopic liver transplantation. However, in some instances, chiefly in the setting of metabolic diseases, transplantation of individual cells, specifically functional hepatocytes, can be an acceptable alternative. The gold standard for this therapy is the use of primary human hepatocytes, isolated from livers that are not suitable for whole organ transplantations. Unfortunately, primary human hepatocytes are scarcely available, which has led to the evaluation of alternative sources of functional hepatocytes. In this review, we will compare the ability of most of these candidate alternative cell sources to engraft and repopulate the liver of preclinical animal models with the repopulation ability found with primary human hepatocytes. We will discuss the current shortcomings of the different cell types, and some of the next steps that we believe need to be taken to create alternative hepatocyte progeny capable of regenerating the failing liver.
topic hepatocyte transplantation
preclinical mouse models for liver damage
primary human hepatocytes
hepatocyte expansion
ipscs
mscs
url https://www.mdpi.com/2073-4409/9/3/566
work_keys_str_mv AT tinetricot alternativecellsourcesforliverparenchymarepopulationwheredowestand
AT jolandeboeck alternativecellsourcesforliverparenchymarepopulationwheredowestand
AT catherineverfaillie alternativecellsourcesforliverparenchymarepopulationwheredowestand
_version_ 1725136769320484864